Rationale and clinical results of inhibiting interleukin-5 for the treatment of severe asthma
Severe asthma is responsible for considerable morbidity and a high proportion of the healthcare costs attributable to asthma. Management is not straightforward as the clinical, pathological and physiological features are heterogeneous and the relationships between these features are poorly understoo...
Main Authors: | Berair, R, Pavord, I |
---|---|
Formato: | Journal article |
Idioma: | English |
Publicado em: |
2013
|
Registos relacionados
-
Rationale and clinical results of inhibiting interleukin-5 for the treatment of severe asthma.
Por: Berair, R, et al.
Publicado em: (2013) -
Interleukin-5 inhibitors for severe asthma: Rationale and future outlook.
Por: Shrimanker, R, et al.
Publicado em: (2017) -
Evidence for the efficacy and safety of anti- interleukin-5 treatment in the management of refractory eosinophilic asthma
Por: Xue, L, et al.
Publicado em: (2015) -
Interleukin-5 in the Pathophysiology of Severe Asthma
Por: Corrado Pelaia, et al.
Publicado em: (2019-12-01) -
Elevated sputum interleukin-5 and submucosal eosinophilia in obese individuals with severe asthma.
Por: Desai, D, et al.
Publicado em: (2013)